Ones To Watch News
Refine Search
Biotechnology
Arcturus Therapeutics, a US messenger RNA (mRNA) company focused on the development of infectious disease vaccines, saw its shares rocket up nearly 24% to $22.63 yesterday on news of what could be an up to $4.5 billion deal relating to its technology. 3 November 2022
Pharmaceutical
Rigel Pharmaceuticals’ share were up 3.4% at $0.75 yesterday, after it announced encouraging top-line efficacy and safety results from the FOCUS Phase III clinical trial of fostamatinib in hospitalized COVID-19 patients without respiratory failure who have certain high-risk prognostic factors. 2 November 2022
Biotechnology
US pharma major AbbVie communicated during its third-quarter financial results on October 28, that it has decided to stop the development of cedirogant (ABBV-157), an oral RORg inverse agonist jointly discovered by French firm Inventiva and AbbVie for the treatment of autoimmune diseases. 1 November 2022
Biotechnology
Having soared as much as 164% earlier in the day, shares of USA-based Coeptis Therapeutics closed down 45% at $6.50 on the Nasdaq, after it announced the completion of its business combination with Bull Horn Holdings, a special purpose acquisition company (SPAC). 1 November 2022
Pharmaceutical
Since 1996 when the tissue plasminogen activator (tPA) – Boehringer Ingelheim’s Actilyse - was approved, there have been nothing but failed attempts at developing a safe and effective treatment for ischemic stroke, according to Pharmazz. 31 October 2022
Biotechnology
A new gene therapy start-up, Eudora, has been launched by the Anglo-American genome writing company Replay. 31 October 2022
Biotechnology
Sino-American biotech BeiGene claims significant progress in its efforts to unlock global opportunities for its Brukinsa (zanubrutinib) with recent regulatory approvals in six Latin American countries. 31 October 2022
Biotechnology
US biotech Y-mAbs Therapeutics (Nasdaq: YMAB) saw its shares plunge more than 30% to $6.20 in after-hours trading on Friday, after it announced a negative outcome of the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting, which reviewed investigational Omblastys (131I-omburtamab) for the treatment of CNS/leptomeningeal metastasis from neuroblastoma. 29 October 2022
Biotechnology
US immuno-oncology cell therapy company 2seventy bio’s shares gained 3.5% to $16.00 this morning, as it announced a strategic alliance with Chinese biotech JW Therapeutics. 27 October 2022
Biotechnology
Australia’s largest biotech CSL Limited today revealed it has entered into a strategic option and license agreement with Arizona, USA-based Translational Sciences for rights to its enhanced thrombus (blood clot) dissolving drug candidate, TS23. 26 October 2022
Biotechnology
Japanese pharma major Astellas Pharma has announced a strategic investment to support the advancement of Texas, USA-based Taysha Gene Therapies’ adeno-associated virus (AAV) gene therapy development programs for the treatment of Rett syndrome and giant axonal neuropathy (GAN). 25 October 2022
Biotechnology
US biotech Mirum Pharmaceuticals edged up 2.6% to $20.02 yesterday, as it released positive top-line data from its Phase III MARCH-PFIC trial evaluating Livmarli (maralixibat) in rare pediatric disease progressive familial intrahepatic cholestasis (PFIC). 25 October 2022
Pharmaceutical
Following its previous rejection of Sumitomo Pharma’s full acquisition proposal, endocrinology specialist Myovant Sciences has now accepted an increased offer from the Japanese major, with the news pushing its shares up 9% to $26.72 this morning. 24 October 2022
Pharmaceutical
ARS Pharmaceuticals has pleased its acquirer with the news that the US regulator will review its lead drug candidate. 24 October 2022
Pharmaceutical
Positive safety and efficacy data from a pivotal Phase III clinical trial have just been published in leading nephrology journal Kidney International, and lend further support to the recent European launch of Kinpeygo (budesonide; development name: Nefecon). 21 October 2022
Biotechnology
US immunology focussed biotech Immunic saw is shares plunge nearly 75% to $2.34 post-market yesterday, after it reported disappointing early-stage results for its psoriasis candidate. The overall trial is ongoing and remains blinded. 21 October 2022
Biotechnology
US clinical-stage biotech Minerva Neurosciences (Nasdaq: NERV) has recently received a refusal to file letter from the Food and Drug Administration (FDA) regarding its new drug application (NDA) for roluperidone, which was filed in August, for the treatment of negative symptoms in patients with schizophrenia, is yet another obstacle to the drug’s development. 21 October 2022
Biotechnology
Following a Series A financing of $27 million a year ago, Singapore-based AUM Biosciences has entered into an agreement to merge with Mountain Crest Acquisition Corp, a publicly-traded special purpose acquisition company (SPAC). 21 October 2022
Biotechnology
Spanish plasma-derived medicines company Grifols ( today announced that its drug Tavlesse (fostamatinib) has a been recommended by UK health technology assessor the National Institute for Health and Care Excellence (NICE) to treat chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments. 19 October 2022
Biotechnology
Cambridge, USA-based clinical-stage biotech Synlogic has announced positive top-line data from its Phase II Synpheny-1 study in phenylketonuria (PKU). 19 October 2022
Biotechnology
Epitopea, a UK and Canada-based cancer immunotherapeutics company, has partnered with nucleic acid delivery specialist Genevant Sciences to develop new RNA-based therapies targeting proprietary tumor antigens. 20 December 2024
Pharmaceutical
US biotech Assembly Biosciences has announced an equity investment of $20.1 million by Gilead Sciences to purchase additional common stock in the company and an amendment to their collaboration to advance the research and development of novel antiviral therapies with $10 million in accelerated funding. 20 December 2024
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze